Category: Stock Market

Shares in Westgold Resources Ltd (ASX: WGX) are trading higher after the company pulled the trigger on a $145 million expansion of its Higginsville processing hub in Western Australia.

The company said in a statement to the ASX that the decision followed a definitive feasibility study on the plan, and it marked a major step towards the company’s strategy to enhance cash flow by increasing production and reducing operating costs.

Production up and costs down

The Higginsville expansion project will increase Westgold’s Southern Goldfields gold production by about 60,000 ounces per year, and reduce processing costs by 24% to $34 per tonne of ore.

Westgold said the expansion had a pre-tax payback period of 21 months at a gold price of $4905, or just 12 months if the current spot gold price was used.

The expansion includes a new primary crusher, a new mill, a pebble crusher, and additional leaching tanks to take processing capacity to 2.6 million tonnes of ore per year, up 62.5%.

The new infrastructure would also support future expansion to 4 million tonnes of ore per year, the company said.

Westgold Managing Director Wayne Branwell said the expansion made sense.

The Higginsville Expansion Plan (HXP) is the next step to drive down unit costs and increase group free cash flow from the Southern Goldfields. By expanding the Higginsville mill capacity to a nominal 2.6Mtpa we are creating a more productive, lower-cost processing hub to match the growing outputs from our Beta Hunt mine. This will see us deliver higher group gold production at a lower cost, in line with our 3-Year Outlook.

Mr Bramwell said the definitive feasibility study showed the expansion plan was robust, but importantly, it was designed with the future in mind.

Strategically, the HXP has been designed with future growth in mind. While nameplate capacity of the enhanced flowsheet stands at 2.6Mtpa, many of the upgrades within the flowsheet such as the ore conveying systems, jaw crusher and SAG mill apron feeder are designed to support further expansion to 4Mtpa. This ensures milling capacity is not an impediment to future mine expansions at prospects such as the Fletcher and Mason Zones at Beta Hunt. With the study complete and final investment decision approved, our focus now shifts to securing long-lead items, progressing EPC tendering and maintaining operational continuity throughout the build. The timing of the HXP aligns strategically with the anticipated growth in mining rates from the Southern Goldfields, ensuring that expanded processing capacity is ready to accommodate increased ore delivery from Beta Hunt.

The current expansion plans are expected to boost production from mid-2028.

Westgold Resources shares were 4.2% higher in early trade at $6.50. The company was valued at $5.91 billion at the close of trade on Monday.   

The post This ASX gold stock is trading higher after greenlighting expansion plans appeared first on The Motley Fool Australia.

More reading

• Westgold Resources gives green light to $145m Higginsville expansion
• 3 shares dumped from the ASX 200 index (and 3 new additions)
• If gold is a safe haven, why are ASX 200 gold stocks like Northern Star and Evolution Mining getting smashed this week?
• Westgold Resources posts record profit and revenue for H1 FY26
• This stellar ASX stock is up 211% this past year — and there’s more growth ahead

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Tuesday.

At the time of writing, the ASX 200 share is up 7% to $3.52 after the company released a clinical trial update.

What did the ASX 200 share announce?

This morning, Clarity revealed that its registrational Phase III AMPLIFY clinical trial has now exceeded its target number of participants.

The AMPLIFY trial is investigating the diagnostic performance of the company’s 64Cu-SAR-bisPSMA PET imaging agent in detecting recurrence of prostate cancer in men whose prostate-specific antigen (PSA) levels are rising following initial treatment.

According to the release, the trial has now consented more participants than originally planned following strong demand from clinical trial sites across the United States and Australia. As a result, consenting of new patients has stopped while the ASX 200 share finalises screening and confirms the final enrolment numbers.

AMPLIFY began in May 2025 and originally aimed to enrol approximately 220 participants. The study is being conducted across multiple clinical sites and will assess imaging at two different timepoints, on the same day and roughly 24 hours after administration.

The results from this pivotal study are expected to support a future application to the US Food and Drug Administration (FDA) seeking approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent for prostate cancer recurrence.

Why this milestone matters

Clinical trials like AMPLIFY are an important step in the regulatory pathway for new medical products. By successfully recruiting the required number of participants, the ASX 200 share has moved a step closer to potentially commercialising its imaging agent in the United States.

The AMPLIFY results will also complement earlier studies, including the Phase I/II COBRA and Phase II Co-PSMA trials, which demonstrated strong imaging capabilities compared with existing standard-of-care PSMA PET scans.

The company’s executive chair, Dr Alan Taylor commented:

We are about to enter the realm of a select few Australian companies who have developed a drug at the benchtop of Australian science and completed an international Phase III clinical trial with that drug, taking us one step closer to commercialisation. Our team is excited to have reached this initial recruitment milestone in the AMPLIFY trial in just 9 months since we imaged our first participant in the study. This is no small feat, given we achieved this phenomenal pace of recruitment despite three SOC products already in the market, commercialised by four different companies.

True to our commitment to the highest standards of clinical research, we recruited participants at numerous different sites across the US and Australia to ensure the trial reflected the broad patient population, real-world clinical settings and various PET cameras in which this product is intended to be used. This strategy required careful planning to allow for all participating sites to contribute to the recruitment, based on allocation of participant numbers to be enrolled per site, resulting in what we believe will be a robust and well-balanced dataset and supporting the integrity and quality of the AMPLIFY study.

The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

More reading

• Why this speculative ASX stock could rocket 68%
• Why Clarity Pharmaceuticals, EOS, Nuix, and Reece shares are racing higher today
• Why is this ASX 300 stock jumping 14% on Monday?
• Why this ASX 300 stock could be a buy after ‘a breakthrough moment’
• Guess which ASX 300 stock is jumping 18% on big news

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

These 2 S&P/ASX 200 Index (ASX: XJO) shares explored new depths on Monday.

Treasury Wine Estates Ltd (ASX: TWE) and Lendlease Group Ltd (ASX: LLC) fell 4.2% and 3.1% respectively, sliding to fresh 52-week lows. Treasury Wine has lost 58% of its value over the past 12 months, while Lendlease has dropped 38% over the same period.

Now the big question is: Can these two ASX 200 shares stage a recovery?

Treasury Wine Estates: US and China headwinds

The ASX 200 share has been under pressure as weaker US demand for luxury wine weighs on sales. Elevated inventories and shifting consumer habits, including moderation trends and softer discretionary spending, have also created headwinds.

The company has additionally been navigating the after-effects of China’s earlier tariffs on Australian wine. Although those tariffs have been removed, rebuilding brand momentum and distribution in China will take time.

Despite this, the ASX 200 wine share still owns globally recognised brands such as Penfolds. Management has also been pushing deeper into the luxury and premium segments, which typically deliver stronger margins.

If demand improves and the Chinese market continues reopening, the strategy could support a recovery in earnings over time.

Analysts remain divided on the ASX 200 share, with most of them sitting on the fence. The average 12-month price target is $5.41, implying a 31% upside from the current share price of $4.13.

Lendlease: Structural global property challenges

Meanwhile, Lendlease has been grappling with structural challenges across global property markets. Higher interest rates have pressured real estate valuations and made development projects more expensive to fund.

At the same time, the ASX 200 share has been undertaking a sweeping strategic reset, selling assets and simplifying its operations to reduce risk and strengthen its balance sheet.

Even so, Lendlease retains significant expertise in large-scale urban development, with projects spanning Australia, Europe, and the US. The company is also focusing on recycling capital and concentrating on markets where it believes it has the strongest competitive advantage.

If property markets stabilise and the restructuring delivers the intended efficiencies, the ASX 200 share could emerge leaner and better positioned for growth.

Despite the share price slump, analysts still see upside for the property stock if the restructuring delivers improved returns.

Broker forecasts currently place the average 12-month price target at around $5.30, implying potential upside of about 44% from recent levels if property markets stabilise.

Foolish Takeaway

Broker sentiment toward the two ASX 200 shares is mixed. Some analysts see value emerging after their steep share price declines, while others remain cautious until there is clearer evidence that earnings and market conditions are improving.

For investors with a long-term mindset, both Treasury Wine Estates and Lendlease could yet prove to be turnaround stories, but patience may be required before confidence fully returns.

The post Can these 2 ASX 200 shares bounce back after hitting fresh lows? appeared first on The Motley Fool Australia.

More reading

• Why I think these cheap ASX shares could be strong buys
• 3 ASX shares down 30% (or more) to buy right now
• 3 shares dumped from the ASX 200 index (and 3 new additions)
• 3 ASX 200 shares trading well below brokers’ targets
• Which billionaire has upped his stake in Treasury Wine Estates?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Fortescue Ltd (ASX: FMG) shares are marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) iron ore giant closed yesterday trading for $19.05. In early morning trade on Tuesday, shares are changing hands for $19.32 apiece, up 1.4%.

For some context, the ASX 200 is up 1.3% at this same time.

The Aussie mining giant should be enjoying some modest tailwinds today from the overnight uptick in global iron ore prices. Iron ore gained 1.2% to be trading at US$102.80 per tonne.

Before market open, investors also learned that Fortescue is succeeding in growing its copper footprint. The miner reported that it has now completed the acquisition of all the shares it did not yet already own in Canadian-listed Alta Copper Corp (TSX: ATCU).

The right copper assets could help boost Fortescue shares longer term, with demand for the red metal widely forecast to remain strong over the decade ahead amid the ongoing global push towards electrification.

Copper is currently trading for US$12,862 per tonne, up 35% over 12 months.

Now, here’s what’s happening with Fortescue and Alta Copper.

Fortescue shares increasing copper exposure

Fortescue first announced its intention to acquire the remaining 64% of Alta Copper on 15 December.

This morning, Fortescue confirmed that its wholly owned subsidiary, Nascent Exploration, has completed that acquisition.

Alta Copper shareholders received C$1.40 per share (AU$1.45) in cash, implying a total equity value of approximately C$139 million.

Offering a potential longer-term boost to Fortescue shares, the ASX 200 miner is now the 100% owner of the Canariaco Copper Project. Located in Peru, Canariaco covers 91 square kilometres of what management labelled “highly prospective tenure” with several deposits.

Fortescue said it is well placed to advance the project, with the Aussie miner having been active in Latin America since 2018. The company also pointed to its well-established technical, permitting, and community engagement expertise.

What did management say?

Commenting on the acquisition that looks to be offering a lift to Fortescue shares, Growth and Energy CEO Gus Pichot said, “Copper is a core pillar of Fortescue’s growth and diversification strategy and the acquisition of Alta Copper builds on our existing critical minerals exploration activity.”

Pichot added:

In particular, the Canariaco Copper Project strengthens Fortescue’s copper portfolio and provides exposure to a significant undeveloped resource within an emerging porphyry corridor in Northern Peru.

Our immediate focus will be on technical reviews, community engagement and advancing the studies required to inform future development decisions.

With today’s intraday moves factored in, Fortescue shares are up 22.1% over 12 months, not including dividends.

The post Fortescue shares lifting off today amid big copper news appeared first on The Motley Fool Australia.

More reading

• 1 beaten-down ASX share to consider buying today, and 5 I’m shunning for now
• Here’s the earnings forecast out to 2030 for Fortescue shares
• 2 ASX 200 shares that turned a $5,000 investment into $10 million
• Did you catch what happened with the Fortescue share price in February?
• Here’s the dividend forecast out to 2030 for Fortescue shares

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I always like to look across the ASX share market for opportunities when there is a sell-off like we’ve seen in recent times.

In the technology space, AI worries have sent some valuations by down more than 50%, which could be very enticing for brave, bargain-hunting investors. Share prices are starting to recover in the tech space.

It’s not common for most of the share market to go down simultaneously, which is when indiscriminate selling occurs. Valuations become cheaper and too low to ignore. That’s when clear opportunities can arise.

I put some of my investing money into the following ASX share names.

Guzman Y Gomez Ltd (ASX: GYG)

Guzman Y Gomez is one of the rapidly growing quick service restaurant (QSR) operators in Australia. It already has more than 200 locations in Australia, as well as a few locations in Singapore, Japan and the US.

The Guzman Y Gomez share price has fallen significantly over the past six months, yet it’s generating more network sales than ever.

Its FY26 half-year result did not excite the market. Total network sales increased by 18%, operating profit (EBITDA) grew 29.6% and net profit after tax (NPAT) increased by 44.9%.

While the ASX share’s overall profitability is increasing, the business is investing in expansion in the US, which is currently seeing operating losses. It’s aiming to grow the sales at its US locations, which will then make them profitable and demonstrate ‘proof of concept’.

I’m not sure what its short-term growth numbers will be like, but I like how it continues to grow its Australian and global restaurant networks. Over the long-term, it’s aiming for 1,000 Guzman Y Gomez locations in Australia, which gives the business significant growth potential over the next two decades.

As a bonus, it’s paying dividends to shareholders. So, as the company’s earnings increase, its dividend payouts can increase as well.

According to the projection on Commsec, the business could generate earnings per share (EPS) of 33.7 cents in FY27 and 46.6 cents in FY28. That means the Guzman Y Gomez share price is trading at 57x FY27’s estimated earnings and 41x FY28’s estimated earnings, at the time of writing.  

L1 Long Short Fund Ltd (ASX: LSF)

The other ASX share investment I made last week was this listed investment company (LIC). It invests in a mixture of ASX shares and international shares on behalf of shareholders.

One of the reasons I like it is because it utilises both long-term investing and short-selling to generate investment returns, allowing it to create positive portfolio profits in all market conditions.

At a time of elevated volatility, there’s an opportunity to pick up bargains in the local and global market. I like how the L1 team invest, particularly with the focus on businesses with lower price/earnings (P/E) ratios.

In its latest monthly update, it said it’s seeing opportunities in areas like infrastructure, golds, US cyclicals, uranium and ‘quality value’.

L1 said:

…we are finding more compelling opportunities in ‘Value’ stocks. We believe low P/E stocks will strongly outperform high P/E stocks (in general) over the coming 1-2 years, which the portfolio is well positioned to benefit from.

As a bonus, the ASX share is steadily increasing its dividend. I’m currently predicting the grossed-up dividend yield for FY26 could be 4.75%, including franking credits, at the time of writing.

The post Why I just invested in these 2 exciting ASX shares appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Guzman Y Gomez, Lovisa, and Newmont shares
• 32 ASX shares about to go ex-dividend
• Here are the top 10 ASX 200 shares today
• These ASX 200 stocks are trading close to 52 week lows: Is it time to buy low?
• These are the 10 most shorted ASX shares

Motley Fool contributor Tristan Harrison has positions in Guzman Y Gomez and L1 Long Short Fund. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Orica Ltd (ASX: ORI) shares are moving higher on Tuesday morning.

At the time of writing, the leading mining and infrastructure solutions provider’s shares are up 2.5% to $22.18.

Why is this ASX 200 share rising?

Investors have been buying Orica’s shares following the release of a positive first-half business update and the announcement of a new cost reduction program.

According to the release, the strong momentum seen in its business during FY 2025 has continued into the first five months of FY 2026.

As a result, the ASX 200 share expects first-half earnings before interest and tax (EBIT) to be slightly higher than the prior corresponding period.

Management advised that this performance reflects strong demand for its premium blasting products and advanced blasting technologies, as well as consistent operational performance across its global manufacturing network.

However, some headwinds remain. A stronger Australian dollar and lower Indonesian coal production quotas are expected to weigh slightly on earnings from the Blasting Solutions division.

Digital and chemicals divisions performing strongly

The ASX 200 share highlighted particularly strong growth in its Digital Solutions business.

Orica said increasing adoption of its digital offerings and recurring revenue growth are expected to drive an approximately 20% increase in EBIT for this segment compared with the prior period.

Meanwhile, its Specialty Mining Chemicals division is also performing well, supported by strong demand for sodium cyanide in the gold mining sector. Following upgrades to its Winnemucca production facility in the United States, Orica expects EBIT for this segment to rise by around 15% year on year.

$100 million cost reduction program

Alongside the trading update, Orica also announced a new organisation-wide program aimed at reducing its cost base. The initiative is expected to deliver at least $100 million in annualised cost savings over the next three years.

Management said the program is designed to position the ASX 200 share for the next phase of sustained profitable growth.

Orica managing director and CEO, Sanjeev Gandhi, said:

I am pleased with the strong start to the underlying business in the 2026 financial year. Our performance reflects the resilience of our business, and the strength of our integrated offering, operational reliability across our global manufacturing network and the ongoing adoption of our premium products, digital solutions and value-added services.

Despite a more volatile operating environment and increasing geopolitical complexity, we have continued to support customers by leveraging our global footprint, maintaining continuity of supply and focusing on operational excellence. Whilst market conditions remain dynamic, we’re confident in the strong fundamentals of our business and our ability to continue to execute our strategy. We remain focused on disciplined capital management and rebasing our costs while advancing our growth initiatives and delivering sustainable value for customers and shareholders.

The post Guess which ASX 200 share is storming higher on business update appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Orica, Origin Energy, and Pro Medicus shares
• Broker names 3 ASX shares to buy this week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Ramsay Health Care Ltd (ASX: RHC) shares have been outperforming large parts of the market lately.

The healthcare stock fell 6.2% to $41.76 on Monday — yet the bigger picture tells a different story. Despite the pullback, it’s still up 18% over the past month.

Ramsay Health Care shares are comfortably outperforming the S&P/ASX 200 Index (ASX: XJO), which has slipped 3.2% over the same period.

Investors are increasingly warming to Ramsay Health Care shares as signs emerge that its long-awaited earnings recovery could finally be gathering pace.

Competitive scale with ageing population

Ramsay is Australia’s largest private hospital operator, running more than 70 hospitals and healthcare facilities across the country and maintaining a large international footprint in Europe and the UK.

That scale gives the company a powerful competitive position in a sector where demand tends to grow steadily over time as populations age and healthcare needs expand.

More patients, increased case complexity

The company’s latest financial results highlighted why investors are starting to pay attention again. It reported strong first-half FY26 results, with improvements across key metrics that were well received by investors.

Revenue for the six months to 31 December 2025 rose 9.7% to $9.34 billion, driven by higher patient activity and increased case complexity across its network.

Profit for Ramsay Health Care shares also rebounded, with net profit after tax reaching $160.7 million, compared with a loss a year earlier. Underlying EBIT increased 7.3% to $536.7 million.

Exploring options for European hospital

While that level of profit growth might not appear spectacular at first glance, the market is focusing on the bigger picture. Ramsay is benefiting from improving hospital utilisation rates, stronger revenue indexation in Australia, and ongoing operational improvements.

Another factor driving optimism for the Ramsay Health Care shares is the company’s strategic repositioning. Management has been exploring options for its European hospital arm, Ramsay Santé. Investors hope that simplifying the group and focusing more heavily on core Australian operations could unlock value and improve margins in the years ahead.

Healthcare demand itself remains a powerful tailwind. With ageing populations and rising demand for surgical procedures, many analysts expect long-term patient volumes to keep increasing.

Private hospitals are a critical part of Australia’s healthcare system. Ramsay’s large network gives it significant bargaining power with insurers and the ability to spread costs across a vast operating footprint.

Labour costs main challenge

Still, the investment case for Ramsay Health Care shares is not without risk. Labour costs remain one of the biggest pressures facing hospital operators globally. Ramsay employs 90,000 staff, and wage inflation has been squeezing margins across the healthcare sector.

Investors should also remember that Ramsay’s earnings growth has been uneven in recent years. While revenue has continued to expand, profits have historically been more volatile due to cost pressures and operational disruptions.

What next for Ramsay Health Care shares?

Ramsay Health Care has returned to profitability and is expanding margins — a clear sign that momentum is improving.

Strong cash flow and rising dividends highlight tighter financial discipline, while its scale across Australia and Europe means earnings aren’t reliant on a single market. Earnings are forecast to grow strongly in the coming years. Projections suggest profits could expand by more than 30% annually as margins recover and operational efficiencies improve. 

Broker sentiment remains mixed on Ramsay Health Care shares. Across the market, the stock carries a hold rating. The average 12-month price target sits at $42.56 per share, which suggests a 2% upside.

The post Here’s why Ramsay Health Care shares have been demolishing the stock market appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• 32 ASX shares about to go ex-dividend
• Buy, hold, sell: HMC Capital, Ramsay Health Care, and Sigma shares
• 5 of the best ASX 200 stocks to buy and hold in February revealed
• What is Morgans saying about Ramsay Healthcare and Karoon Energy shares?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are catching the eye on Tuesday.

In morning trade, the radiopharmaceuticals company’s shares are up 14% to $11.62.

Why are Telix shares jumping?

Investors have been bidding the company’s shares higher this morning after it released the results from part one of the ProstACT Global Phase 3 study. This is the safety and dosimetry lead-in for its therapeutic candidate, TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan).

According to the release, the company has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.

In addition, key findings include a tolerability profile supported by dosimetry and low-grade non-hematologic events, lesion dosimetry that indicates no difference in absorbed dose profile across cohorts, no adverse drug-drug interactions observed in TLX591-Tx combinations, and hematologic events are in line with expectations, transient, and manageable, with similar rates of recovery across all patient cohorts.

Telix highlights that the results from part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

The patient population comprised prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) patients previously treated with one androgen receptor pathway inhibitor (ARPI).

Telix advised that it has already advanced the study into Part 2, which is a 2:1 randomised treatment expansion, in jurisdictions where the clinical trial has obtained approval from health authorities.

Part 1 data will be presented to the United States (U.S.) Food and Drug Administration (FDA) to seek an Investigational New Drug (IND) amendment to progress part 2 in the U.S.

Commenting on the news, Telix’s group chief medical officer, David N. Cade, MD, said:

Despite advances in clinical practice, men with advanced prostate cancer still need improved first and second line treatment options. These results build on prior findings and highlight the potential for TLX591-Tx in combination with contemporary standard of care, to become a new first-line option for patients facing this aggressive disease. We are encouraged by the data and look forward to engaging with the FDA at the earliest opportunity, while continuing to advance enrollment in Part 2 in regions where clinical trial initiation has already been approved.

Neeraj Agarwal from the Huntsman Cancer Institute in Salt Lake City, and the ProstACT Global Principal Investigator, said:

These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic adverse events, further supports the tolerability profile of this investigational therapy.

The post Telix shares jump 14% on big news appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results
• Here are the top 10 ASX 200 shares today
• 2 Aussie stocks primed to surge in 2026
• Here are the top 10 ASX 200 shares today
• 3 ASX 200 shares to buy and hold for a decade or more

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

So… Oil was up 27% yesterday to ~$116 a barrel.

Now down 5% to $86.

The S&P futures were down 1.8% last night, and the US market closed up 0.8% this morning.

The ASX lost 2.9%, but futures suggest we might make most of that back, today.

Thing is? It’s not unusual. Volatility is all-too common.

I don’t know what comes next. No-one does.

Instead? Focus on the long term.

Sources: OilPrice.com, Google, CommSec

Fool on!

The post What happened to the crash? appeared first on The Motley Fool Australia.

More reading

• Why is this ASX 200 share charging 7% higher today?
• Can these 2 ASX 200 shares bounce back after hitting fresh lows?
• Fortescue shares lifting off today amid big copper news
• Why I just invested in these 2 exciting ASX shares
• Guess which ASX 200 share is storming higher on business update

Motley Fool contributor Scott Phillips has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Good news: The ASX is up 7.4% over the past 12 months, plus probably somewhere around 4% more for dividends.

So let’s call it a total gain of 11.4%, give or take.

That’s better than the market’s long term average of just over 9% (depending on your source and the start date, but it’s about right over the past 120 years (per Credit Suisse / UBS) and the last 30 (according to Vanguard).

Beauty. Pop the champagne and…

Oh? That’s not the news you’re seeing and hearing today?

You’re seeing something different? A lot of carry-on about a one-day fall?

Yeah, me too.

Which is kinda understandable, but also…  a little too short-term, I reckon.

Yes, big falls make news.

Yes, we feel the pain of losses two- or three times more than the joy we get from similar gains.

Yes, we worry that one bad day might lead to more.

Yes, sometimes that happens, and things get worse.

Yes, sometimes a lot worse… for a long time.

And yet.

And yet, the market is up over 11% over the past 12 months. Plus franking credits.

It is up 25% over the past 5 years, plus something like 20% more in dividends. (That’s 45%, close enough to 9% per annum, as as simple average. Less, compounded, but then you have to compound the dividends… so close enough for our purposes).

But that’s chicken-feed.

The Vanguard data I mentioned before?

9.3% per annum, on average, over the 30 years to 30 June 2025 (the most recent data available).

Or, if you prefer dollars rather than percentages (I do!), enough to have turned $10,000 into $143,000 (before fees and taxes).

You’d reckon that should be the headline story every day, right?

Now, the realists among you will reply with one of two thoughts. Either:

1. It wouldn’t be a headline because it’s taken 30 years to happen; and/or

2. No-one would click on it.

True, and true.

And yet, that is the far, far more useful and powerful stat, rather than worrying about what happened today.

Here’s the other thing: yes, oil was up more than 28% in a single day earlier today. That is absolutely notable.

But here’s the other thing.

The headlines say ‘Oil over $100 per barrel for the first time since…’.

The alternative headline? ‘Oil has cost less than $100 a barrel for every day in between’.

See, framing matters.

No, we’re not being taken for mugs (necessarily) by the headline writers. And they’re not wrong.

The clue is in the first three letters of the word ‘news’.

It’s not their job to provide long-term perspective. I mean, a little wouldn’t hurt, but again, the clue is in the name.

It’s our job, as investors, to bring the common sense. To bring the timeframe that’s all too often missing in the rest of the conversation.

The market probably fell 3% or more in a single day a few dozen times over the 30 years during which that 14-fold return occurred.

Each of those times would have felt scary, unsettling, and like they might be the harbinger of something worse.

Here’s the thing: sometimes they even were.

And yet, that 14-fold return was the long term return.

That is, as I’ve repeatedly written: astounding long term gains accrue despite, not in the absence of these sorts of things.

Not only that, but if you don’t remain invested, and try to guess when the next ups and downs will come, you risk missing out on those astonishing gains!

I can’t make investing anxiety-free. I can’t make the volatility go away.

I can’t tell you whether today’s falls will be a one-off, or the beginning of something worse.

And frankly, I can’t tell you if the future is going to look like the past, either.

But isn’t that the most likely outcome?

Every time the market fell, someone said ‘it’s different this time’. The circumstances might have been, but the outcomes never were.

So sure, maybe ‘it’s different this time’, but I doubt it.

Today’s falls aren’t fun. Losing money isn’t fun.

(There’s a silver lining if you’re still adding to your portfolio – prices are cheaper today! – but that doesn’t help if you’re in retirement and living off the proceeds of your portfolio.)

Tomorrow?

I have no idea what it’ll bring. Maybe things get worse. Maybe they bounce back.

The same for the next week, month and year, for that matter.

But over the long term? Well, unless we’ve hit peak human ingenuity, I suspect the market will be higher in 5 years, much higher in 10 years, and higher again in 20 and 30 years.

And if that’s true, obsessing over daily, weekly, monthly or even yearly falls is understandable… but not very productive.

I can’t make the process easy to endure, unfortunately, but I suspect that endurance will pay off handsomely.

My best advice? Learn from history, then keep your eyes on the horizon.

And I reckon the future is bright.

Fool on!

The post The good news you won’t read today – but really should appeared first on The Motley Fool Australia.

More reading

• 3 ASX ETFs with a focus on global defensive shares
• Westgold Resources gives green light to $145m Higginsville expansion
• Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results
• Bell Potter names the best ASX dividend shares to buy in March
• Rotating into defensive stocks? 3 ASX companies to consider

Motley Fool contributor Scott Phillips has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.